How Clinical Cancer Trials Work in the UK Henry Kitchener, University of Manchester ANZGOG March 2013.

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

UK Clinical Research Network (UKCRN) UK Clinical Research Network Maxine Stead PhD UKCRN Assistant Director – Clinical Trials.
1 Attributing the costs of health & social care Research & Development – Understanding AcoRD Trudi Simmons Senior Manager – Research Finance & Programmes.
We need user-led research more now than ever before…
HJMUKMF Spring Day – 13 March 2013 Early Phase Clinical Trial Network UKMF Spring Day - 13 March 2013.
Attributing the costs of health Research & Development – AcoRD Elizabeth Coote Head of Non-Commercial Research Services TASC NRS – delivering.
“Best Research for Best Health” Andrew Riley Managing Director.
Welcome to the NIHR Peter Knight, Deputy Director Research Contracting, Information Intelligence and Stakeholder Engagement NIHR Trainees Meeting Leeds.
Clinical trials in Europe Emma Greenwood, Policy Manager Thursday 23 rd February.
A new pathway for the regulation and governance of health research Professor Deborah Ashby Co-Director of Imperial Clinical Trials Unit School of Public.
Professor Mark R Baker.  Strategic context  Service organisation in England  The research agenda  Drivers for the review  Main findings  Options.
Managing Sponsorship Research Services University of Oxford.
Research Ethics-Integrity-Governance. University Initiative:The Catalyst? ‘02 Good Research Practice Standards & Procedure to Investigate Potential Research.
Delivery of clinical trials through managed networks
1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical develop- ment Phase I Phase II Phase III Product.
Supporting research to make patients, and the NHS, better Update on Clinical Research Network Performance - time for further improvement Dr Jonathan Sheffield.
The Benefits of a Research Active Trust. What is Research? Research is about finding out something new and innovative by combining theory with evidence.
Medical Research BADRAG meeting Jan 2013 Dr H Sari-Kouzel.
Consultant Pharmacists
Debbie Greer Research Development Officer Warwick Medical School Research Support Services
NIHR Delivering Better Health 26 November 2013, Leeds Dr David Cox Deputy Director – Research Finance & Programmes.
Diabetes Clinical and Translational Research: Rewards and Challenges Ruth S. Weinstock MD PhD Medical Director, Joslin Diabetes Center and Clinical Research.
Barriers and Facilitators to Clinical Trial Research in Australia Google images Michael Friedlander.
The NIHR Stroke Research Network Supporting research to make patients, and the NHS, better The NIHR Stroke Research Network Judith Williamson and Zena.
Dr David Jackson Clinical Lead for Research YCRN Co-director WYCLRN Yorkshire Palliative Medicine Regional Learning Group April 2008 Clinical Research.
CML SPIRIT 3 Steve O’Brien Northern Institute for Cancer Research Newcastle University Medical School Newcastle, March 2013.
Upper GI Research and Clinical Trials Update Bridget Workman Research Manager NECRN N 21 ST November 2012.
Stakeholders In Clinical Research The Pharma Company Professor Phil Warner.
Experimental Cancer Medicine – the future of cancer care Rosie Davies (LECMC RP based at RLUH) Janet Davies (LECMC RP based at CCO)
Diabetes Education Network Scotland Donald Pearson 3 rd June 2009.
100k Genomes Project In December 2012 the Prime Minister announced a programme of Whole Genome Sequencing as part of the UK Government’s Life Sciences.
Lymphoedema Management: the Northern Ireland Model Jane Rankin Regional Lead Lymphoedema Network Northern Ireland (LNNI) February 2010.
Barriers to innovation – and solutions The Collaboration Conundrum Colette Goldrick, Director ABPI Northern Ireland.
Developing a National Critical Care Clinical Research Network: what’s in it for trainees? Paul Dark Associate Professor, Faculty of Medical and Human Sciences,
Introducing DeNDRoN East Anglia
Developing medicines for the future and why it is challenging Angela Milne.
Adam Heathfield, PhD Senior Director, Worldwide Policy, Pfizer Inc. September 25, 2013 Personalised Medicine – an industry perspective.
National Cancer Survivorship Initiative Central Hall, Westminster Monday 21 September 2009 Children and Young People.
Presentation/Phenotype
Metrics do matter !. To measure is to know.. Opportunity to convert performance data into information and then action.
Access to drugs, Reducing bottlenecks Matt Cooper Business Development & Marketing Director NIHR Clinical Research Network
NIHR Themed Call Prevention and treatment of obesity Writing a good application and the role of the RDS 19 th January 2016.
HTA Efficient Study Designs Peter Davidson Head of HTA at NETSCC.
New drug approvals vs.Pharmaceutical R&D expenditures New drug approvals (dots), and pharmaceutical R&D expenditures (shaded area), in the United States.
Research for Patient Benefit Preparing a research proposal What makes a good proposal? Professor Scott Weich, Panel Chair.
Research Training Opportunities for Medical and Non-Medical Professionals NIHR Research Design Service East Midlands & University of Leicester Clinical.
NIHR Southampton Biomedical Research Centre The Southampton Biomedical Research Centre is funded by the National Institute for Health Research (NIHR) and.
Coming Soon – the MRC Framework for the Development, Design and Analysis of Stratified Medicine Research Dr David Crosby MRC Programme Manager for Methodology.
Building the NIHR NIHR: 10 years of delivering health and care research for the nation QEII Centre, London Wednesday 18 May 2016 Professor Dame Sally C.
Research Networks – opportunities for SLTs Dr Caroline Pickstone, Senior Manager, SY CLRN.
Health Research: promote it, use it, do it Lynne Goodacre Assistant Director NHS Research & Development North West.
ELIGIBILITY CRITERIA- Summarised
London (South) Comprehensive Local Research Network
SWAG SSG Lung Cancer Meeting
Point of Care Testing for Personalised Medicine and Health
Reducing bias in randomised controlled trials involving therapists:
Cancer & Nutrition NIHR infrastructure collaboration
Designing Research that Improves Health and Wellbeing for All How the NIHR Research Design Service North East can help.
Achieving World-Class Cancer Outcomes A Strategy for England
Working Collaboratively in Cancer Research Sarah Nicholson Research Lead CHUGGS & Hope Facility Manager UHL Lynne Howells Translational Research Manager.
Achieving World-Class Cancer Outcomes A Strategy for England
SWAG SSG Sarcoma Cancer Meeting
Myeloma UK Clinical Trial Network (CTN)
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Achieving World-Class Cancer Outcomes A Strategy for England
An Introduction to the NIHR programmes
Achieving World-Class Cancer Outcomes A Strategy for England
Challenges of Recruitment in Haematology Trials
Precision Medicine A New Era Hazem Assi American University of Beirut
CORE: A randomised trial of COnventional care versus Radioablation (stereotactic body radiotherapy (SBRT)) in Extracranial oligometastases (CRUK/14/038)
Presentation transcript:

How Clinical Cancer Trials Work in the UK Henry Kitchener, University of Manchester ANZGOG March 2013

Background  The NHS has a vast budget which requires evidence to define standards of care  The UK government understands this and is really committed to evidence based medicine  NICE defines standards of care with national guidance  This may be misconstrued as ”rationalising” but funding does require evidence of cost effectiveness.

Background  UK has a prominent history of clinical trials.  The public have a supportive view and understand the importance of trials.  There is adequate funding for trials.  There is enthusiasm amongst clinical investigators.  UK is therefore fertile soil for clinical trials.

Source of funding gynaecological cancer trials  CRUK  Funds Phase II and III trials through CTAAC.  new trials per year, across all cancer.  Focus is on survival outcomes.  NIHR HTA  Funds mainly Phase III trials across all of clinical medicine.  For cancer, focuses more on screening, quality of life, and prevention outcomes.  Commercial  Pharma sponsored studies and investigator led studies which a public body sponsors.

Funding model  Direct costs; salaries & oncosts  Indirect costs; admin & estates charges  Consumables; essential materials  Service support; additional investigations over standard of care  “Excess treatment” costs; cost of the intervention if it were adopted after the trial. This also applies to screening.

Funding model CharitiesTreasuryPharmaHealth “Authoritiy” Direct costs  Indirect costs  Consumables  Service support  (sponsored)Local Research Network Excess treatment costs 

Trial funding  Trials funded by the Treasury, the AMRC and “approved” investigator led Pharma trials are put on the National Portfolio.  National Portfolio trials qualify for support of research nurses. Funded through NCRN  Trust obtain public R&D funding for recruiting to clinical trials.

Trial costs  “Full economic costs” are part of the funding model of Universities  CRUK up to £100K/year to cover direct costs  NIHR HTA typically fund more complex trials which with FEC are £ K per year.

Clinical trials in the UK  UK “suffers” from heavy regulation and hurdles to overcome.  Despite this trials are seen as the most direct route to influencing standard of care.  Can underpin a successful career  “Impact” is increasingly the gold standard for effective R&D but  Trials do require considerable determination and motivation.

InterGroup Trials  Funders do understand the need for international participation.  The GCIG is respected beyond the Gynae Cancer community.  Funding is available for trials led from ANZGOG as well as from the UK; recent examples  PARAGON (ANZGOG)  IP Chemotherapy (NCIC)

The Future  Need to reduce bureaucracy  Targeted therapy  Biomarker led interventions (personalised medicine)  More complex trial design  More expensive trials  Molecular pathology (GCLP)  Biobanking